Vestal Point Capital, LP Acquires 5% Stake in Bright Minds Biosciences Inc.

Vestal Point Capital, LP and its Managing Partner, Ryan Wilder, have filed a Schedule 13G indicating a new 5.0% ownership stake in Bright Minds Biosciences Inc. (DRUG). As of the event date on March 31, 2026, the reporting persons beneficially own 492,319 common shares. The position is held through a fund and a managed account for which Vestal Point Capital, LP serves as the investment adviser. Ryan Wilder, as the Chief Investment Officer and Managing Partner of the investment manager, shares voting and dispositive power over these securities. The filing states that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The percentage ownership is based on approximately 9.79 million common shares outstanding as of February 12, 2026. This filing represents a new significant holding for the investment group in the biotechnology firm.